Premium
The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline
Author(s) -
Loeffen Erik A.H.,
Dalen Elvira C.,
Mulder Renée L.,
de Wetering Marianne D.,
Kremer Leontien C.M.,
Tissing Wim J.E.
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26867
Subject(s) - medicine , guideline , anthracycline , grading (engineering) , duration (music) , intensive care medicine , clinical practice , evidence based medicine , quality of evidence , cancer , alternative medicine , meta analysis , physical therapy , breast cancer , pathology , art , civil engineering , literature , engineering
We aimed to provide recommendations on the infusion duration of anthracycline chemotherapy agents in children with cancer. This study also serves as a practice example of the essential steps that need to be taken when using a previously published systematic review to develop a high‐quality clinical practice guideline. Although evidence was scarce and included adult studies, the panel was able (using the Grading of Recommendations Assessment, Development and Evaluation evidence‐to‐decision framework) to recommend in favor of an anthracycline infusion duration of at least 1 hr (strong recommendation, very low to moderate quality of evidence). Recommending a precise optimal prolonged infusion duration was currently not possible.